NEURONTIN Drug Patent Profile

✉ Email this page to a colleague

When do Neurontin patents expire, and when can generic versions of Neurontin launch?

Neurontin is a drug marketed by Viatris and is included in three NDAs.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neurontin

A generic version of NEURONTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for NEURONTIN?
What are the global sales for NEURONTIN?
What is Average Wholesale Price for NEURONTIN?

Summary for NEURONTIN

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	126
Patent Applications:	4,475
Drug Prices:	Drug price information for NEURONTIN
Drug Sales Revenues:	Drug sales revenues for NEURONTIN
What excipients (inactive ingredients) are in NEURONTIN?	NEURONTIN excipients list
DailyMed Link:	NEURONTIN at DailyMed

Drug patent expirations by year for NEURONTIN

Recent Clinical Trials for NEURONTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dianne Lou	Phase 1/Phase 2
Viatris Specialty LLC	Phase 4
CAMC Health System	Phase 4

See all NEURONTIN clinical trials

Pharmacology for NEURONTIN

Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for NEURONTIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-001	Dec 30, 1993	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129-001	Mar 2, 2000	AA	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NEURONTIN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	⤷ Sign Up	⤷ Sign Up
Viatris	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	⤷ Sign Up	⤷ Sign Up
Viatris	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for NEURONTIN

See the table below for patents covering NEURONTIN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Ireland	903089		⤷ Sign Up
Mexico	PA03009392	COMPOSICION FAMACEUTICA LIQUIDA. (LIQUID PHARMACEUTICAL COMPOSITION.)	⤷ Sign Up
Australia	3267889		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for NEURONTIN

Recent Clinical Trials for NEURONTIN

Pharmacology for NEURONTIN

Make Better Decisions: Try a trial or see plans & pricing